Durvalumab is a selective, high-affinity human IgG1κ monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80.29 Objective response rates of approximately 12% have been reported with durvalumab monotherapy in EGFR TKI-resistant tumours with strong PD-L1 expression.30 We hypothesised that the combination of gefitinib with durvalumab would exert therapeutic synergy by inducing differentiation and engraftment of memory T cells immediately after initial TKI treatment, therefore inducing more durable clinical remissions with the EGFR TKI. This evidence concerns the gene PDCD1 and neoplasm.